Regeneus appoints Japan-based non-executive director with extensive pharmaceutical industry experience

Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.

Leo is a senior executive with over 20 years of experience in pharmaceutical innovation, commercialization, regulation and policy development. He has worked in North America and Asia and has spent the last 12 years living and working in Japan. Leo is President of Merck Serono, Japan and was previously the President of Allergan, Japan.

View the full announcement via the ASX here.